高コレステロール血症患者における pravastatin の赤血球 aggregability に対する影響

概要

論文の詳細を見る
Erythrocyte aggregation is one of the most important hemorheological factors which are related to pathogenesis of cerebral infarction or ischemic heart disease. The purpose of this study was to investigate the effect of pravastatin (HMG-CoA reductase inhibitor) on erythrocyte aggregability (RBC-A) in patients with hypercholesterolemia. The subjects comprised 8 patients (3 males and 5 females, 68±10 yeas old) with hypercholesterolemia above 230mg/dl. Pravastatin (10mg/day) was administered orally for 8 weeks. The RBC-A was measured using the whole blood RBC aggregometer developed by us (Am J Physiol 251: H1205-H1210, 1986) with concomitant measurement of blood factors such as hematocrit, concentrations of total protein, total cholesterol and fibrinogen, and albumin-globulin ratio (A/G ratio). The RBC-A values before, at 4 weeks after and at 8 weeks after the pravastatin administration were 0.152±0.024 s-1, 0.154±0.033 s-1, and 0.145±0.019 s-1 respectively. The RBC-A value at 8 weeks after pravastatin administration was significantly (p<0.05) lower than that before administration. At 8 weeks after pravastatin administration, total cholesterol showed significant decrease and the other blood factors showed no changes compared with those before pravastatin administration. The above results indicate that pravastatin improves erythrocyte aggregability in patients with hypercholesterolemia.
特定非営利活動法人日本バイオレオロジー学会の論文

高コレステロール血症患者における pravastatin の赤血球 aggregability に対する影響

スポンサーリンク

概要

著者

関連論文

スポンサーリンク